Canada approves generic semaglutide

Semaglutide is the drug behind Ozempic — one of the biggest diabetes medicines on the planet, and one of the most expensive. The problem in Canada has been simple: huge demand, very little price competition, and a lot of patients paying brand-name prices. This week, that changed. Health Canada approved Dr. Reddy’s generic semaglutide injection for adults with Type 2 diabetes, which makes it the first generic version cleared in Canada and the first approved anywhere in the G7. (canada.ca) ### What actually got approved? Not a weight-loss free-for-all. The approval is for a once-weekly semaglutide injection indicated for adults with Type 2 diabetes to help manage blood sugar — basically the generic version of Ozempic’s diabetes use, not a blanket approval for every semaglutide use case. Health Canada said the product met its standards for safety, efficacy, and quality for generic drugs. (canada.ca) ### Why is this a big deal in Canada? Because Canada had a weird opening that most big markets did not. Novo Nordisk’s semaglutide protection in Canada weakened earlier than many people expected, and by January 2026 the path for generic entry was open. That made Canada the obvious place for generic drugmakers to move first. Now one of them has actually crossed the line from “could launch” to “has regulatory approval.” (labiotech.eu) ### Why Dr. Reddy’s first? Dr. Reddy’s says it received a Notice of Compliance ahead of Health Canada’s review target date, which matters because being first into a newly opened market can shape pharmacy contracts, wholesaler relationships, and doctor familiarity. The approval covers 2 mg/pen and 4 mg/pen presentations, and the company says launch preparations are already underway. (morningstar.com) ### Does this mean prices drop immediately? Probably not overnight — but the direction is obvious. Health Canada says generic medicines in Canada are often 45% to 90% cheaper than brand-name versions. That does not guarantee semaglutide will fall by that exact amount right away, because launch pricing, provincial reimbursement, and supply all matter. But once a blockbuster drug gets a real generic foothold, the pricing conversation changes fast. (canada.ca) ### Why not expect instant abundance? Because approval is not the same thing as broad shelf availability. Dr. Reddy’s still has to launch, supply pharmacies, and scale distribution. Semaglutide is also not an easy generic — Health Canada calls these “complex synthetic products,” which is a polite way of saying they are harder to make and harder to replicate consistently than a basic tablet. (canada.ca) ### Will more competitors show up? Yes — and that may matter as much as this first approval. Health Canada says it is reviewing eight other generic semaglutide submissions from different companies and expects more decisions in the coming weeks and months. One generic matters. A queue of generics matters much more, because that is when price pressure usually gets real. (canada.ca) ### What does this change for patients? For Canadians with Type 2 diabetes, this is the first real sign that semaglutide could stop being a luxury-tier medicine for people paying out of pocket. It does not solve access by itself, and it does not mean every insurer or province will move instantly. But it turns a patent story into a pharmacy story — and that is when patients usually start to feel the difference. (canada.ca) ### Bottom line? Canada just became the first G7 country to approve a generic semaglutide. The headline is one approval. The bigger story is that a market built around one blockbuster brand is starting to crack open. (canada.ca)